Weily Soong, MD
Allergy/ Immunology · Birmingham, ALNPI 1316981608
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by AstraZeneca at 25.7% of the total.
Across 1,705 payments — averaging $411.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$180K
- Genentech USA, Inc.$72K
- Regeneron Healthcare Solutions, Inc.$62K
- AbbVie$61K
- Sanofi$47K
- Novartis$46K
- plus $233K from 45 others
Across 1,596 payments — averaging $3124.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.2M
- AstraZeneca$555K
- LEO Pharma AS$477K
- Novartis$420K
- AbbVie$354K
- Sanofi US Services Inc.$316K
- plus $1.7M from 20 others
What the payments were for
- Consulting fees$239,21734%
- Speaking & faculty fees$377,67754%
- Travel & lodging$49,5217%
- Food & beverage$34,7955%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 91 | $269,129 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 31 | $153,097 |
| HyqviaIgg/Hyaluronidase,recombinant | 26 | $144,336 |
| Dupixent PenDupilumab | 36 | $137,980 |
| Dupixent SyringeDupilumab | 28 | $124,797 |
| FasenraBenralizumab | 17 | $100,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $75,925 |
| RinvoqUpadacitinib | 12 | $75,519 |
| TezspireTezepelumab-Ekko | 13 | $58,928 |
| NucalaMepolizumab | 12 | $41,405 |
| Epinephrine | 77 | $19,359 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $18,409 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,039 |
| Cromolyn Sodium | 23 | $10,286 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $587 | $269,12991 claims |
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort | $180,382 | $181,58173 claims |
| Grifols USA, LLCGamunex-C | $6,328 | $153,09731 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $1,013 | $144,33626 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $16,759 | $131,369158 claims |
| AbbVieRinvoq | $61,354 | $75,51912 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $19,35977 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $90 | $10,28623 claims |
| Boehringer IngelheimSpiriva Respimat | $70 | $9,44815 claims |
| MerckDulera | $14 | $5,19114 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $10,985 | $4,94316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Birmingham
- Clara ChungBirmingham$7K
- Joseph LarussaBirmingham$1K
- James MalletteFlorence$843
- Paul MottaDothan$717
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.